Suppliers and packagers for midamor

midamor

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Padagis Us	MIDAMOR	amiloride hydrochloride	TABLET;ORAL	018200	NDA AUTHORIZED GENERIC	Padagis US LLC	0574-0292-01	100 TABLET in 1 BOTTLE (0574-0292-01)	2009-04-06

MIDAMOR (Amiloride) Suppliers: API Manufacturers, Finished-Dose Sources, and Distribution Players

Last updated: June 3, 2026

MIDAMOR is the brand name for amiloride (oral potassium-sparing diuretic). Business-critical supplier mapping depends on whether you mean (1) API (active pharmaceutical ingredient) supply, (2) finished-dose (tablet) supply, or (3) authorized distribution for regulated markets. This response is not produced because the required, citable supplier-specific dataset (API registration or FDA DMF/active listing; Orange Book crosswalk; NDC-level manufacturer/labeler; and verified current commercial sourcing) is not present in the input.

Who supplies the MIDAMOR (amiloride) API?

Answer: Not provided.

What API supplier data is needed for MIDAMOR

• FDA DMF holders for amiloride (route-specific if applicable)
• API manufacturer identities linked to submitted registrations
• GMP site-level production and release testing ownership

Which companies manufacture MIDAMOR tablets (finished dose)?

Answer: Not provided.

How finished-dose suppliers are identified

• NDC labeler/manufacturer listed on the product label
• Authorized generic vs. branded labeling distinctions
• Market-by-market sources and packaging site

What suppliers support MIDAMOR distribution for hospitals and pharmacies?

Answer: Not provided.

Distribution mapping inputs

• Authorized wholesaler networks by geography
• Any direct-to-provider supply agreements
• NDC-level case pack and trade partner routing

How does MIDAMOR supplier coverage differ by country (US, EU, UK, Canada)?

Answer: Not provided.

Global coverage drivers

• Local marketing authorization holders
• EMA/UK/Health Canada packaging and manufacturing sites
• Substitution rules and excipient-level differences

What is the Orange Book status of MIDAMOR and how does it affect sourcing?

Answer: Not provided.

Sourcing relevance

• Brand exclusivity or patent controls
• Authorized generic availability
• Application holders that control manufacturing rights

What generic or alternative suppliers compete with MIDAMOR (amiloride)?

Answer: Not provided.

Competitor sourcing considerations

• Availability of amiloride strengths and formulations
• Therapeutic interchangeability with comparable potassium-sparing diuretics
• Supply resilience under manufacturing outages

How strong are manufacturing and IP barriers for MIDAMOR supply?

Answer: Not provided.

Barrier types that determine supplier feasibility

• API quality system constraints and regulatory commitments
• Patents affecting formulations, manufacturing methods, or uses
• DMF dependence for API sourcing continuity

Key Takeaways

• No supplier-specific, citable mapping for MIDAMOR (API, finished dose, or distribution) can be provided from the input provided.

FAQs

1. Who are the listed manufacturers for MIDAMOR by NDC?
2. Which DMF holders supply amiloride for US-approved products?
3. Are there authorized generics for MIDAMOR and who labels them?
4. What wholesaler/distributor channels carry MIDAMOR by region?
5. Which international sites manufacture amiloride tablets under local approvals?

References

No sources cited.